A Phase 2 interventional study of Placebo and Selgantolimod in Chronic Hepatitis B, sponsored by Gilead Sciences. Completed at 10 sites in 3 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-05-10.
Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Hepatitis B, Chronic by Gilead Sciences — none open to participants now, 2 under way, 1 of them phase 3. Hepatitis B, Chronic · Gilead Sciences.
Among the 34 studies in Hepatitis B, Chronic by Gilead Sciences, this one is the 22nd largest by enrollment of the 29 interventional ones that give a count, is one of 3 that started in 2018, is one of 15 in phase 2, and was the 32nd registered.
899 studies on the registry are indexed under Hepatitis B, Chronic; 154 are open to participants now.
Browse Hepatitis B, Chronic studies →None of the 34 studies in Hepatitis B, Chronic by Gilead Sciences is open now. The open studies under Hepatitis B, Chronic, anywhere →
Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 67 is below the median of 100 across 660 interventional studies indexed under Hepatitis B, Chronic.
Median enrollment 112 across the 29 interventional studies, 174 across the 4 observational. Of the 31 that completed or were terminated, 24 (77%) have results posted.
This tab as a report to print or save as PDF → With an account.
Gilead Sciences is the lead sponsor of 693 studies on the registry; 27 are open to participants now.
Of its 262 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 34 studies in Hepatitis B, Chronic by Gilead Sciences, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objectives of this study are to evaluate the safety and tolerability of multiple oral doses of selgantolimod and to evaluate the antiviral activity of selgantolimod in adult participants with chronic hepatitis B (CHB) who are viremic and not currently being treated.
Key Inclusion Criteria:
Key Exclusion Criteria:
Individuals meeting any of the following laboratory parameters at screening:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with Hepatitis B e antigen (HBeAg)-positive CHB or HBeAg-negative CHB currently not on oral antiviral (OAV) treatment, will receive selgantolimod 3 mg (2 x 1.5 mg tablet) on the same day once weekly for 24 doses along with tenofovir alafenamide (TAF) 25 mg once daily for 24 weeks. After the 24th dose, selgantolimod will be discontinued, and participants will continue to receive TAF until Week 48/early discontinuation (ED). At Week 48, per Principal Investigator's (PI's) discretion, participants can continue in the Treatment Free Follow-Up (TFFU) phase for up to an additional 48 weeks.
Drug: Selgantolimod · Drug: TAF
Participants with HBeAg-positive CHB or HBeAg-negative CHB currently not on OAV treatment, will receive selgantolimod 1.5 mg (1 x 1.5 mg tablet) and placebo (1 tablet) on the same day once weekly for 24 doses along with TAF 25 mg once daily for 24 weeks. After the 24th dose, selgantolimod will be discontinued, and participants will continue to receive TAF until Week 48/ED. At Week 48, per PI's discretion, participants can continue in the TFFU phase for up to an additional 48 weeks.
Drug: Placebo · Drug: Selgantolimod · Drug: TAF
Participants with HBeAg-positive CHB or HBeAg-negative CHB currently not on OAV treatment, will receive 2 tablets of placebo on the same day once weekly for 24 doses along with TAF 25 mg once daily for 24 weeks. After the 24th dose, placebo will be discontinued, and participants will continue to receive TAF until Week 48/ED. At Week 48, per PI's discretion, participants can continue in the TFFU phase for up to an additional 48 weeks.
Drug: Placebo · Drug: TAF
Tablet(s) administered orally every 7 days for 24 doses in fasted state
Tablet(s) administered orally every 7 days for 24 doses in fasted state
Also known as: GS-9688
Tablet(s) administered orally once daily with food
Also known as: Vemlidy®
Percentage of Participants With ≥ 1 log10 IU/mL Decline in Serum Quantitative Hepatitis B Surface Antigen (qHBsAg) From Baseline at Week 24
Time frame: Baseline, Week 24
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)
An AE was any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An AE was any unfavorable and unintended sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the investigational medicinal product. A TEAE was defined as any AE with an onset date on or after the first dose date and no later than 30 days after permanent discontinuation of selgantolimod/placebo; or any AE leading to premature discontinuation of study drugs.
Time frame: First dose date up to Week 24 plus 30 days
Percentage of Participants With Treatment-Emergent Laboratory Abnormalities
Treatment-emergent laboratory abnormalities were defined as values that increased at least 1 toxicity grade from baseline at any postbaseline time point, up to and including the date of the last dose of study drug plus 30 days for selgantolimod/placebo at Week 24. If the relevant baseline laboratory value was missing, any abnormality of at least Grade 1 observed within the time frame specified above was considered treatment emergent. Clinical laboratory results were graded according to Gilead Grading Scale for Severity of Adverse Events and Laboratory Abnormalities.
Time frame: First dose date up to Week 24 plus 30 days
Percentage of Participants With ≥ 1 log10 IU/mL Decline in Serum qHBsAg From Baseline at Week 4
Time frame: Baseline, Week 4
Percentage of Participants With ≥ 1 log10 IU/mL Decline in Serum qHBsAg From Baseline at Week 8
Time frame: Baseline, Week 8
Percentage of Participants With ≥ 1 log10 IU/mL Decline in Serum qHBsAg From Baseline at Week 12
Time frame: Baseline, Week 12
Percentage of Participants With ≥ 1 log10 IU/mL Decline in Serum qHBsAg From Baseline at Week 48
Time frame: Baseline, Week 48
Change From Baseline in Serum qHBsAg at Week 4
Time frame: Baseline, Week 4
Change From Baseline in Serum qHBsAg at Week 8
Time frame: Baseline, Week 8
Change From Baseline in Serum qHBsAg at Week 12
Time frame: Baseline, Week 12
Change From Baseline in Serum qHBsAg at Week 24
Time frame: Baseline, Week 24
Change From Baseline in Serum qHBsAg at Week 48
Time frame: Baseline, Week 48
Percentage of Participants With Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) < Lower Limit of Quantification (LLOQ) at Week 12
LLOQ was defined as 20 IU/mL.
Time frame: Week 12
Percentage of Participants With HBV DNA < LLOQ at Week 24
LLOQ was defined as 20 IU/mL.
Time frame: Week 24
Percentage of Participants With HBV DNA < LLOQ at Week 48
LLOQ was defined as 20 IU/mL.
Time frame: Week 48
Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Week 12
HBsAg loss was defined as qualitative HBsAg changing from positive at baseline to negative at a postbaseline visit.
Time frame: Week 12
Percentage of Participants With HBsAg Loss at Week 24
HBsAg loss was defined as qualitative HBsAg changing from positive at baseline to negative at a postbaseline visit.
Time frame: Week 24
Percentage of Participants With HBsAg Loss at Week 48
HBsAg loss was defined as qualitative HBsAg changing from positive at baseline to negative at a postbaseline visit.
Time frame: Week 48
Percentage of Participants With HBeAg Loss and Seroconversion at Week 12
HBeAg loss was defined as qualitative HBeAg changing from positive at baseline to negative at a postbaseline visit. HBeAg seroconversion was defined as Hepatitis B e antibody (HBeAb) loss and anti-HBe change from negative/missing at baseline to positive at a postbaseline visit.
Time frame: Week 12
Percentage of Participants With HBeAg Loss and Seroconversion at Week 24
HBeAg loss was defined as qualitative HBeAg changing from positive at baseline to negative at a postbaseline visit. HBeAg seroconversion was defined as HBeAb loss and anti-HBe change from negative/missing at baseline to positive at a postbaseline visit.
Time frame: Week 24
Percentage of Participants With HBeAg Loss and Seroconversion at Week 48
HBeAg loss was defined as qualitative HBeAg changing from positive at baseline to negative at a postbaseline visit. HBeAg seroconversion was defined as HBeAb test changing from negative or missing at baseline to positive at a postbaseline visit.
Time frame: Week 48
Percentage of Participants With Virologic Breakthrough From Baseline up to Week 24
Virologic breakthrough was defined as confirmed HBV DNA ≥ 69 IU/mL after having been \< 69 IU/mL or confirmed HBV DNA ≥ 1 log10 IU/mL increase from nadir.
Time frame: Baseline up to Week 24
Percentage of Participants With Virologic Breakthrough From Baseline up to Week 48
Virologic breakthrough was defined as confirmed HBV DNA ≥ 69 IU/mL after having been \< 69 IU/mL or confirmed HBV DNA ≥ 1 log10 IU/mL increase from nadir.
Time frame: Baseline up to Week 48
Percentage of Participants With Drug Resistance Mutations
Time frame: Baseline up to Week 48
Pharmacokinetic (PK) Parameter: AUClast of Selgantolimod
AUClast is defined as the concentration of drug from time zero to the last observable concentration.
Time frame: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose at Day 1 and Week 23
PK Parameter: AUC0-24 of Selgantolimod
AUC0-24 is defined as the concentration of drug over time from time zero to time 24 hours.
Time frame: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose at Day 1 and Week 23
PK Parameter: AUCinf of Selgantolimod
AUC0-inf is defined as the concentration of drug over time from time zero to infinity.
Time frame: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose at Day 1 and Week 23
PK Parameter: Cmax of Selgantolimod
Cmax is defined as the maximum concentration of drug.
Time frame: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose at Day 1 and Week 23
PK Parameter: Tmax of Selgantolimod
Tmax is defined as the time (observed time point) of Cmax.
Time frame: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose at Day 1 and Week 23
PK Parameter: CL/F of Selgantolimod
CL/F is defined as the apparent oral clearance following administration of the drug.
Time frame: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose at Day 1 and Week 23
PK Parameter: t1/2 of Selgantolimod
t1/2 is defined as the estimate of the terminal elimination half-life of the drug.
Time frame: Predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 8, and 24 hours postdose at Day 1 and Week 23
Participants were enrolled at study sites in Canada, South Korea, and Taiwan. The first participant was screened on 28 August 2018. The last study visit occurred on 12 April 2021.
| Milestone | Selgantolimod 3 mg + TAF | Selgantolimod 1.5 mg + TAF | Placebo + TAF |
|---|---|---|---|
| Started | 26 | 28 | 13 |
| Completed | 26 | 27 | 11 |
| Not completed | 0 | 1 | 2 |
| Withdrew: Withdrew consent | 0 | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 |
| Milestone | Selgantolimod 3 mg + TAF | Selgantolimod 1.5 mg + TAF | Placebo + TAF |
|---|---|---|---|
| Started | 13 | 12 | 2 |
| Completed | 11 | 11 | 2 |
| Not completed | 2 | 1 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 |
| Withdrew: Withdrew consent | 0 | 1 | 0 |
| percentage of participants | Selgantolimod 3 mg + TAF | Selgantolimod 1.5 mg + TAF | Placebo + TAF |
|---|---|---|---|
| Percentage of Participants With ≥ 1 log10 IU/mL Decline in Serum Quantitative Hepatitis B Surface Antigen (qHBsAg) From Baseline at Week 24 | 0 | 0 | 0 |
An AE was any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An AE was any unfavorable and unintended sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the investigational medicinal product. A TEAE was defined as any AE with an onset date on or after the first dose date and no later than 30 days after permanent discontinuation of selgantolimod/placebo; or any AE leading to premature discontinuation of study drugs.
| percentage of participants | Selgantolimod 3 mg + TAF | Selgantolimod 1.5 mg + TAF | Placebo + TAF |
|---|---|---|---|
| Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) | 84.6 | 60.7 | 76.9 |
Treatment-emergent laboratory abnormalities were defined as values that increased at least 1 toxicity grade from baseline at any postbaseline time point, up to and including the date of the last dose of study drug plus 30 days for selgantolimod/placebo at Week 24. If the relevant baseline laboratory value was missing, any abnormality of at least Grade 1 observed within the time frame specified above was considered treatment emergent. Clinical laboratory results were graded according to Gilead Grading Scale for Severity of Adverse Events and Laboratory Abnormalities.
| percentage of participants | Selgantolimod 3 mg + TAF | Selgantolimod 1.5 mg + TAF | Placebo + TAF |
|---|---|---|---|
| Percentage of Participants With Treatment-Emergent Laboratory Abnormalities | 84.6 | 92.9 | 92.3 |
| percentage of participants | Selgantolimod 3 mg + TAF | Selgantolimod 1.5 mg + TAF | Placebo + TAF |
|---|---|---|---|
| Percentage of Participants With ≥ 1 log10 IU/mL Decline in Serum qHBsAg From Baseline at Week 4 | 0 | 0 | 0 |
| percentage of participants | Selgantolimod 3 mg + TAF | Selgantolimod 1.5 mg + TAF | Placebo + TAF |
|---|---|---|---|
| Percentage of Participants With ≥ 1 log10 IU/mL Decline in Serum qHBsAg From Baseline at Week 8 | 0 | 0 | 0 |
| percentage of participants | Selgantolimod 3 mg + TAF | Selgantolimod 1.5 mg + TAF | Placebo + TAF |
|---|---|---|---|
| Percentage of Participants With ≥ 1 log10 IU/mL Decline in Serum qHBsAg From Baseline at Week 12 | 0 | 0 | 0 |
| percentage of participants | Selgantolimod 3 mg + TAF | Selgantolimod 1.5 mg + TAF | Placebo + TAF |
|---|---|---|---|
| Percentage of Participants With ≥ 1 log10 IU/mL Decline in Serum qHBsAg From Baseline at Week 48 | 0 | 0 | 0 |
| log10 IU/mL | Selgantolimod 3 mg + TAF | Selgantolimod 1.5 mg + TAF | Placebo + TAF |
|---|---|---|---|
| Change From Baseline in Serum qHBsAg at Week 4 | -0.04 ± 0.155 | -0.01 ± 0.081 | -0.02 ± 0.065 |
| log10 IU/mL | Selgantolimod 3 mg + TAF | Selgantolimod 1.5 mg + TAF | Placebo + TAF |
|---|---|---|---|
| Change From Baseline in Serum qHBsAg at Week 8 | -0.04 ± 0.161 | -0.05 ± 0.121 | 0.00 ± 0.081 |
| log10 IU/mL | Selgantolimod 3 mg + TAF | Selgantolimod 1.5 mg + TAF | Placebo + TAF |
|---|---|---|---|
| Change From Baseline in Serum qHBsAg at Week 12 | -0.04 ± 0.163 | -0.05 ± 0.108 | 0.01 ± 0.099 |
| log10 IU/mL | Selgantolimod 3 mg + TAF | Selgantolimod 1.5 mg + TAF | Placebo + TAF |
|---|---|---|---|
| Change From Baseline in Serum qHBsAg at Week 24 | -0.08 ± 0.198 | -0.11 ± 0.174 | -0.03 ± 0.146 |
| log10 IU/mL | Selgantolimod 3 mg + TAF | Selgantolimod 1.5 mg + TAF | Placebo + TAF |
|---|---|---|---|
| Change From Baseline in Serum qHBsAg at Week 48 | -0.12 ± 0.218 | -0.16 ± 0.235 | -0.12 ± 0.145 |
LLOQ was defined as 20 IU/mL.
| percentage of participants | Selgantolimod 3 mg + TAF | Selgantolimod 1.5 mg + TAF | Placebo + TAF |
|---|---|---|---|
| Percentage of Participants With Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) < Lower Limit of Quantification (LLOQ) at Week 12 | 20.8 | 28.6 | 25.0 |
LLOQ was defined as 20 IU/mL.
| percentage of participants | Selgantolimod 3 mg + TAF | Selgantolimod 1.5 mg + TAF | Placebo + TAF |
|---|---|---|---|
| Percentage of Participants With HBV DNA < LLOQ at Week 24 | 37.5 | 32.1 | 33.3 |
LLOQ was defined as 20 IU/mL.
| percentage of participants | Selgantolimod 3 mg + TAF | Selgantolimod 1.5 mg + TAF | Placebo + TAF |
|---|---|---|---|
| Percentage of Participants With HBV DNA < LLOQ at Week 48 | 50.0 | 44.4 | 45.5 |
HBsAg loss was defined as qualitative HBsAg changing from positive at baseline to negative at a postbaseline visit.
| percentage of participants | Selgantolimod 3 mg + TAF | Selgantolimod 1.5 mg + TAF | Placebo + TAF |
|---|---|---|---|
| Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Week 12 | 0 | 0 | 0 |
HBsAg loss was defined as qualitative HBsAg changing from positive at baseline to negative at a postbaseline visit.
| percentage of participants | Selgantolimod 3 mg + TAF | Selgantolimod 1.5 mg + TAF | Placebo + TAF |
|---|---|---|---|
| Percentage of Participants With HBsAg Loss at Week 24 | 0 | 0 | 0 |
HBsAg loss was defined as qualitative HBsAg changing from positive at baseline to negative at a postbaseline visit.
| percentage of participants | Selgantolimod 3 mg + TAF | Selgantolimod 1.5 mg + TAF | Placebo + TAF |
|---|---|---|---|
| Percentage of Participants With HBsAg Loss at Week 48 | 0 | 0 | 0 |
HBeAg loss was defined as qualitative HBeAg changing from positive at baseline to negative at a postbaseline visit. HBeAg seroconversion was defined as Hepatitis B e antibody (HBeAb) loss and anti-HBe change from negative/missing at baseline to positive at a postbaseline visit.
| percentage of participants | Selgantolimod 3 mg + TAF: HBeAg-positive CHB Participants | Selgantolimod 1.5 mg + TAF: HBeAg-positive CHB Participants | Placebo + TAF: HBeAg-positive CHB Participants |
|---|---|---|---|
| HBeAg Loss | 0 | 0 | 0 |
HBeAg loss was defined as qualitative HBeAg changing from positive at baseline to negative at a postbaseline visit. HBeAg seroconversion was defined as HBeAb loss and anti-HBe change from negative/missing at baseline to positive at a postbaseline visit.
| percentage of participants | Selgantolimod 3 mg + TAF: HBeAg-positive CHB Participants | Selgantolimod 1.5 mg + TAF: HBeAg-positive CHB Participants | Placebo + TAF: HBeAg-positive CHB Participants |
|---|---|---|---|
| HBeAg Loss | 0 | 0 | 0 |
HBeAg loss was defined as qualitative HBeAg changing from positive at baseline to negative at a postbaseline visit. HBeAg seroconversion was defined as HBeAb test changing from negative or missing at baseline to positive at a postbaseline visit.
| percentage of participants | Selgantolimod 3 mg + TAF: HBeAg-positive CHB Participants | Selgantolimod 1.5 mg + TAF: HBeAg-positive CHB Participants | Placebo + TAF: HBeAg-positive CHB Participants |
|---|---|---|---|
| HBeAg Loss | 0 | 0 | 0 |
Virologic breakthrough was defined as confirmed HBV DNA ≥ 69 IU/mL after having been \< 69 IU/mL or confirmed HBV DNA ≥ 1 log10 IU/mL increase from nadir.
| percentage of participants | Selgantolimod 3 mg + TAF | Selgantolimod 1.5 mg + TAF | Placebo + TAF |
|---|---|---|---|
| Percentage of Participants With Virologic Breakthrough From Baseline up to Week 24 | 3.8 | 7.1 | 15.4 |
Virologic breakthrough was defined as confirmed HBV DNA ≥ 69 IU/mL after having been \< 69 IU/mL or confirmed HBV DNA ≥ 1 log10 IU/mL increase from nadir.
| percentage of participants | Selgantolimod 3 mg + TAF | Selgantolimod 1.5 mg + TAF | Placebo + TAF |
|---|---|---|---|
| Percentage of Participants With Virologic Breakthrough From Baseline up to Week 48 | 3.8 | 10.7 | 15.4 |
| percentage of participants | Selgantolimod 3 mg + TAF | Selgantolimod 1.5 mg + TAF | Placebo + TAF |
|---|---|---|---|
| Percentage of Participants With Drug Resistance Mutations | 0 | 0 | 0 |
AUClast is defined as the concentration of drug from time zero to the last observable concentration.
| hr*pg/mL | Selgantolimod 3 mg + TAF | Selgantolimod 1.5 mg + TAF |
|---|---|---|
| Day 1 | 1163.0 ± 833.27 | 548.0 ± 393.00 |
| Week 23 | 1441.8 ± 1601.19 | 491.2 ± 489.29 |
AUC0-24 is defined as the concentration of drug over time from time zero to time 24 hours.
| hr*pg/mL | Selgantolimod 3 mg + TAF | Selgantolimod 1.5 mg + TAF |
|---|---|---|
| Day 1 | 1162.2 ± 832.29 | 547.7 ± 392.77 |
| Week 23 | 1440.5 ± 1598.05 | 494.4 ± 485.56 |
AUC0-inf is defined as the concentration of drug over time from time zero to infinity.
| hr*pg/mL | Selgantolimod 3 mg + TAF | Selgantolimod 1.5 mg + TAF |
|---|---|---|
| Day 1 | 1184.2 ± 843.53 | 556.4 ± 394.38 |
| Week 23 | 1462.8 ± 1616.70 | 503.2 ± 492.66 |
Cmax is defined as the maximum concentration of drug.
| pg/mL | Selgantolimod 3 mg + TAF | Selgantolimod 1.5 mg + TAF |
|---|---|---|
| Day 1 | 373.3 ± 208.63 | 307.7 ± 311.12 |
| Week 23 | 591.0 ± 565.11 | 268.2 ± 254.16 |
Tmax is defined as the time (observed time point) of Cmax.
| hours | Selgantolimod 3 mg + TAF | Selgantolimod 1.5 mg + TAF |
|---|---|---|
| Day 1 | 0.98 (0.50 to 4.10) | 0.53 (0.28 to 1.80) |
| Week 23 | 0.55 (0.28 to 1.10) | 0.50 (0.28 to 0.55) |
CL/F is defined as the apparent oral clearance following administration of the drug.
| mL/hr | Selgantolimod 3 mg + TAF | Selgantolimod 1.5 mg + TAF |
|---|---|---|
| Day 1 | 4094330.4 ± 3034917.79 | 4603039.8 ± 3733427.89 |
| Week 23 | 4550308.6 ± 3858788.24 | 6223868.1 ± 5265428.49 |
t1/2 is defined as the estimate of the terminal elimination half-life of the drug.
| hours | Selgantolimod 3 mg + TAF | Selgantolimod 1.5 mg + TAF |
|---|---|---|
| Day 1 | 4.55 (4.32 to 4.95) | 5.13 (4.29 to 5.47) |
| Week 23 | 4.78 (3.95 to 4.95) | 5.03 (4.76 to 5.10) |
Collected over All-Cause Mortality: Enrollment up to Week 96 Adverse Events: First dose up to last dose of selgantolimod/placebo (Week 24) plus 30 days; or TAF (Week 48) plus 3 days, whichever came later. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Selgantolimod 3 mg + TAF | 0/26 (0%) | 1/26 (3.8%) | 21/26 (80.8%) |
| Selgantolimod 1.5 mg + TAF | 0/28 (0%) | 0/28 (0%) | 15/28 (53.6%) |
| Placebo + TAF | 0/13 (0%) | 0/13 (0%) | 10/13 (76.9%) |
| Event | Selgantolimod 3 mg + TAF | Selgantolimod 1.5 mg + TAF | Placebo + TAF |
|---|---|---|---|
| Limb injuryInjury, poisoning and procedural complications | 1/26 | 0/28 | 0/13 |
| Event | Selgantolimod 3 mg + TAF | Selgantolimod 1.5 mg + TAF | Placebo + TAF |
|---|---|---|---|
| NauseaGastrointestinal disorders | 8/26 | 6/28 | 0/13 |
| VomitingGastrointestinal disorders | 6/26 | 3/28 | 0/13 |
| Upper respiratory tract infectionInfections and infestations | 2/26 | 1/28 | 3/13 |
| FatigueGeneral disorders | 5/26 | 3/28 | 0/13 |
| DizzinessNervous system disorders | 5/26 | 1/28 | 0/13 |
| HeadacheNervous system disorders | 3/26 | 5/28 | 2/13 |
| DiarrhoeaGastrointestinal disorders | 3/26 | 1/28 | 2/13 |
| ChillsGeneral disorders | 4/26 | 0/28 | 0/13 |
| PalpitationsCardiac disorders | 3/26 | 0/28 | 1/13 |
| PruritusSkin and subcutaneous tissue disorders | 3/26 | 0/28 | 0/13 |
The Safety Analysis Set included all participants who took at least 1 dose of the study drug.
| Age, Continuous(years) | Selgantolimod 3 mg + TAF | Selgantolimod 1.5 mg + TAF | Placebo + TAF | Total |
|---|---|---|---|---|
| Mean | 46 ± 10.3 | 44 ± 12.1 | 46 ± 12.0 | 45 ± 11.3 |
| Sex: Female, Male(Participants) | Selgantolimod 3 mg + TAF | Selgantolimod 1.5 mg + TAF | Placebo + TAF | Total |
|---|---|---|---|---|
| Female | 11 | 13 | 4 | 28 |
| Male | 15 | 15 | 9 | 39 |
| Ethnicity (NIH/OMB)(Participants) | Selgantolimod 3 mg + TAF | Selgantolimod 1.5 mg + TAF | Placebo + TAF | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 0 | 1 |
| Not Hispanic or Latino | 26 | 27 | 13 | 66 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Selgantolimod 3 mg + TAF | Selgantolimod 1.5 mg + TAF | Placebo + TAF | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 25 | 28 | 13 | 66 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 0 | 1 |
| White | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Selgantolimod 3 mg + TAF | Selgantolimod 1.5 mg + TAF | Placebo + TAF | Total |
|---|---|---|---|---|
| Canada | 12 | 15 | 6 | 33 |
| South Korea | 7 | 10 | 1 | 18 |
| Taiwan | 7 | 3 | 6 | 16 |
| HBsAg(log10 IU/mL) | Selgantolimod 3 mg + TAF | Selgantolimod 1.5 mg + TAF | Placebo + TAF | Total |
|---|---|---|---|---|
| Mean | 3.8 ± 0.86 | 4.2 ± 0.83 | 4.0 ± 0.73 | 4.0 ± 0.82 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2018 to primary completion in Dec 2019, 15 months.
Results were first posted in Jan 2021, 1 year after primary completion.
Of 75 industry-sponsored phase 2 interventional studies under Hepatitis B, Chronic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 39. This study's 15 months is below that.
Counting every sponsor, half of 87 studies reached it within 23 months; a quarter within 16 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Selgantolimod